(AGENPARL) – Wed 10 December 2025 Press release
Multiple sclerosis: the EU turns to artificial intelligence for increasingly predictive and personalised therapies The threshold of 55,000 MRI scans from 7,500 patients with multiple sclerosis, along with available clinical data across 8 European countries has been surpassed—an impressive volume of information that, thanks to AI, promises to make MS care more predictive and more personalised
Bergamo, December 10, 2025 – Using artificial intelligence (AI) to process a sufficiently large amount of data and build a harmonised database, with the goal of making the clinical management of multiple sclerosis more predictive and tailored to each patient, ultimately improving quality of life and preserving autonomy. This is the work underway within the observational, retrospective study RECLAIM, conducted by researchers from several European partner institutions.
The study integrates real-world healthcare data from routine clinical practice, structured data from observational studies, and data obtained from clinical trials. The construction of the database, launched last year, is continuously evolving. The project has now surpassed 55,000 MRI scans collected from over 7,500 individuals with multiple sclerosis, along with their available clinical data. All MRI data have been quantitatively analysed by icometrix, Belgium. Thanks to this wealth of information—which includes medical history, treatments, relapses, radiological examinations, retinal imaging (OCT), evoked potentials and other biomarkers—it will be possible to develop AI models capable of more accurately predicting disease progression in each patient, identifying the most effective therapies, and distinguishing deterioration due to inflammatory relapses from silent progression.
RECLAIM is conducted within the broader European project CLAIMS (Clinical Impact through AI-assisted MS Care), funded by the Innovative Health Initiative (IHI)—a public–private partnership between the European Commission, industry, and the scientific community—under the EU’s Horizon Europe research and innovation framework. The project brings together 15 organisations, including university hospitals, research institutes, biotech companies and foundations, coordinated by Charité – Universitätsmedizin Berlin. Italy is represented by Casa di Cura IGEA in Milan and ASST Papa Giovanni XXIII in Bergamo, the latter being the only Italian public institution in the consortium.
“The aim is to bring precision medicine into everyday clinical practice, supporting more accurate diagnoses and quicker care pathways, improving therapeutic decisions and the quality of life of people with multiple sclerosis,” explained neurologist Dario Alimonti, principal investigator of the RECLAIM study for ASST Papa Giovanni XXIII. “The expected outcome is precision medicine that works in real life: more targeted therapies, safer decision-making processes and more effective monitoring of the disease, with benefits for both patients and healthcare systems.”
Wim Van Hecke, CEO of icometrix, added: “MRI is essential for tracking silent progression in MS. The CLAIMS project will move the field forward with measurements of both inflammatory and smouldering pathology. This innovative approach is key to enabling data-driven evaluations, giving patients the best chance to preserve their quality of life.”
In the attached images (Credit: icometrix NV):Left: Snapshot of a sample icobrain ms report showing the rendering of segmented lesions and the quantification of lesion and brain volumes. Right: Examples of segmented FLAIR lesions, color-coded by location (top) and by evolution over time (bottom). Credit: icometrix NV.
Davide Cremaschi – Press office ASST Papa Giovanni XXIII